by The global Large Molecule Bioanalytical Testing Services market size is expected to be worth around US$ 4.0 billion by 2030, according to a new report by Vision Research Reports.
Large Molecule Bioanalytical Testing Services Market (By Phase: Preclinical, Clinical; By Type: Pharmacokinetics, ADA, Others; By Test Type: ADME, PK, PD, Bioavailability, Bioequivalence, Other Tests; Therapeutic Area: Oncology, Infectious Diseases, Cardiology, Neurology, Others; By End-user: SMEs, Large Firms) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030
Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/38305
| Report Coverage | Details |
| Market Size | US$ 4.0 billion by 2030 |
| Growth Rate | CAGR of 10.5% From 2021 to 2030 |
| Base year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Phase, Type, Test type, Therapeutic Area, End User |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | Covance, Inc.; IQVIA; Syneos Health; SGS SA; Toxikon; Intertek Group plc; Pace Analytical Services LLC |
Growth Factor
The major factor attributing to market growth is the increased application of bioanalytical testing in clinical trials of biomarkers, large molecules, and others.
Rising prevalence of HIV, infectious disease, and others has led to increasing demand for globally. Moreover, increasing government initiatives to control the outbreak of various infectious diseases such as Corona and Ebola virus is anticipated to offer more opportunities for the market. Hence, the market is expected to grow over the assessment period.
Key Players
- Covance, Inc.
- IQVIA
- Syneos Health
- SGS SA
- Toxikon
- Intertek Group plc
- Pace Analytical Services LLC
Market Segmentation
- Phase Outlook
- Preclinical
- With Antibody
- Without Antibody (ELISA Based Assay)
- Clinical
- Preclinical
- Type Outlook
- Pharmacokinetics
- ADA
- Others
- Test Type Outlook
- ADME
- PK
- PD
- Bioavailability
- Bioequivalence
- Other Tests
- Therapeutic Area Outlook
- Oncology
- Infectious Diseases
- Cardiology
- Neurology
- Others
- End-user Outlook
- SMEs
- CROs & CMOs
- Sponsor Organizations
- Others (Academic Institutes, etc.)
- Large Firms
- CROs & CMOs
- Sponsor Organizations
- Others (Academic Institutes, etc.)
- SMEs
- Regional Outlook
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Asia Pacific
- India
- Japan
- China
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/38305
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Large Molecule Bioanalytical Testing Services Market, By Phase
7.1. Large Molecule Bioanalytical Testing Services Market, by Phase, 2020-2030
7.1.1. Preclinical
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Clinical
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Large Molecule Bioanalytical Testing Services Market, By Type
8.1. Large Molecule Bioanalytical Testing Services Market, by Type, 2020-2030
8.1.1. Pharmacokinetics
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. ADA
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Large Molecule Bioanalytical Testing Services Market, By Test Type
9.1. Large Molecule Bioanalytical Testing Services Market, by Test Type, 2020-2030
9.1.1. ADME
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. PK
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. PD
9.1.3.1. Market Revenue and Forecast (2016-2030)
9.1.4. Bioavailability
9.1.4.1. Market Revenue and Forecast (2016-2030)
9.1.5. Bioequivalence
9.1.5.1. Market Revenue and Forecast (2016-2030)
9.1.6. Other Tests
9.1.6.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Large Molecule Bioanalytical Testing Services Market, By Therapeutic Area
10.1. Large Molecule Bioanalytical Testing Services Market, by Therapeutic Area, 2020-2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Cardiology
10.1.3.1. Market Revenue and Forecast (2016-2030)
10.1.4. Neurology
10.1.4.1. Market Revenue and Forecast (2016-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Large Molecule Bioanalytical Testing Services Market, By End-use
11.1. Large Molecule Bioanalytical Testing Services Market, by End-use, 2020-2030
11.1.1. SMEs
11.1.1.1. Market Revenue and Forecast (2016-2030)
11.1.2. Large Firms
11.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 12. Global Large Molecule Bioanalytical Testing Services Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Phase (2016-2030)
12.1.2. Market Revenue and Forecast, by Type (2016-2030)
12.1.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.1.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.1.5. Market Revenue and Forecast, by End-use (2016-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Phase (2016-2030)
12.1.6.2. Market Revenue and Forecast, by Type (2016-2030)
12.1.6.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.1.6.5. Market Revenue and Forecast, by End-use (2016-2030)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, by Phase (2016-2030)
12.1.7.2. Market Revenue and Forecast, by Type (2016-2030)
12.1.7.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.1.7.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.1.7.5. Market Revenue and Forecast, by End-use (2016-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Phase (2016-2030)
12.2.2. Market Revenue and Forecast, by Type (2016-2030)
12.2.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.2.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.2.5. Market Revenue and Forecast, by End-use (2016-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Phase (2016-2030)
12.2.6.2. Market Revenue and Forecast, by Type (2016-2030)
12.2.6.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.2.6.5. Market Revenue and Forecast, by End-use (2016-2030)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, by Phase (2016-2030)
12.2.7.2. Market Revenue and Forecast, by Type (2016-2030)
12.2.7.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.2.7.5. Market Revenue and Forecast, by End-use (2016-2030)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, by Phase (2016-2030)
12.2.8.2. Market Revenue and Forecast, by Type (2016-2030)
12.2.8.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.2.8.5. Market Revenue and Forecast, by End-use (2016-2030)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, by Phase (2016-2030)
12.2.9.2. Market Revenue and Forecast, by Type (2016-2030)
12.2.9.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.2.9.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.2.9.5. Market Revenue and Forecast, by End-use (2016-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Phase (2016-2030)
12.3.2. Market Revenue and Forecast, by Type (2016-2030)
12.3.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.3.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.3.5. Market Revenue and Forecast, by End-use (2016-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Phase (2016-2030)
12.3.6.2. Market Revenue and Forecast, by Type (2016-2030)
12.3.6.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.3.6.5. Market Revenue and Forecast, by End-use (2016-2030)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, by Phase (2016-2030)
12.3.7.2. Market Revenue and Forecast, by Type (2016-2030)
12.3.7.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.3.7.5. Market Revenue and Forecast, by End-use (2016-2030)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, by Phase (2016-2030)
12.3.8.2. Market Revenue and Forecast, by Type (2016-2030)
12.3.8.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.3.8.5. Market Revenue and Forecast, by End-use (2016-2030)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, by Phase (2016-2030)
12.3.9.2. Market Revenue and Forecast, by Type (2016-2030)
12.3.9.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.3.9.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.3.9.5. Market Revenue and Forecast, by End-use (2016-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Phase (2016-2030)
12.4.2. Market Revenue and Forecast, by Type (2016-2030)
12.4.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.4.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.4.5. Market Revenue and Forecast, by End-use (2016-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Phase (2016-2030)
12.4.6.2. Market Revenue and Forecast, by Type (2016-2030)
12.4.6.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.4.6.5. Market Revenue and Forecast, by End-use (2016-2030)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, by Phase (2016-2030)
12.4.7.2. Market Revenue and Forecast, by Type (2016-2030)
12.4.7.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.4.7.5. Market Revenue and Forecast, by End-use (2016-2030)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, by Phase (2016-2030)
12.4.8.2. Market Revenue and Forecast, by Type (2016-2030)
12.4.8.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.4.8.5. Market Revenue and Forecast, by End-use (2016-2030)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, by Phase (2016-2030)
12.4.9.2. Market Revenue and Forecast, by Type (2016-2030)
12.4.9.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.4.9.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.4.9.5. Market Revenue and Forecast, by End-use (2016-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Phase (2016-2030)
12.5.2. Market Revenue and Forecast, by Type (2016-2030)
12.5.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.5.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.5.5. Market Revenue and Forecast, by End-use (2016-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Phase (2016-2030)
12.5.6.2. Market Revenue and Forecast, by Type (2016-2030)
12.5.6.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.5.6.5. Market Revenue and Forecast, by End-use (2016-2030)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, by Phase (2016-2030)
12.5.7.2. Market Revenue and Forecast, by Type (2016-2030)
12.5.7.3. Market Revenue and Forecast, by Test Type (2016-2030)
12.5.7.4. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
12.5.7.5. Market Revenue and Forecast, by End-use (2016-2030)
Chapter 13. Company Profiles
13.1. Covance, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. IQVIA
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Syneos Health
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. SGS SA
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Toxikon
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Intertek Group plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pace Analytical Services LLC
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
Glossary of Terms
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/38305
About Us: Our team of skilled and experienced analysts specializes in troubleshooting problems faced by our clients. For comprehensive summary of our services and market research requirements for Global industry.
Contact Us:
call: +1 9197 992 333
Vision Research Report
Any Assistance, Email – sales@visionresearchreports.com
